Boston Advisors’s Intersect ENT, Inc XENT Stock Holding History

Boston Advisors’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$426K	Sell	25,035 -14,500	-37%	-$264K	0.02%	474
2019 Q2	$900K	Buy	39,535 +3,230	+9%	+$87.1K	0.05%	381
2019 Q1	$1.17M	Sell	36,305 -5,340	-13%	-$165K	0.06%	318
2018 Q4	$1.17M	Buy	41,645 +7,324	+21%	+$215K	0.07%	284
2018 Q3	$987K	Buy	34,321 +2,697	+9%	+$81K	0.04%	380
2018 Q2	$1.18M	Buy	31,624 +6,703	+27%	+$263K	0.03%	346
2018 Q1	$979K	Sell	24,921 -4,156	-14%	-$152K	0.03%	369
2017 Q4	$942K	Buy	29,077 +580	+2%	+$17.4K	0.02%	375
2017 Q3	$888K	Sell	28,497 -12,056	-30%	-$357K	0.02%	380
2017 Q2	$1.13M	Buy	40,553 +12,463	+44%	+$282K	0.03%	361
2017 Q1	$482K	Buy	+28,090	New	+$393K	0.01%	477

Other funds holding XENT

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boston Advisors's XENT Position: Q3 2019 in Review

Boston Advisors reduced its Intersect ENT, Inc (XENT) stake by 37% in Q3 2019, selling an estimated $264K and leaving 25,035 shares worth $426K. The position accounts for 0.02% of the portfolio, ranked #474.

Boston Advisors first reported a position in XENT in Q1 2017 and has held it in 11 quarters since. The position peaked at $1.18M in Q2 2018. 112 funds tracked by Wall St. Rank hold XENT as of Q3 2019.

Boston Advisors held 25,035 shares of Intersect ENT, Inc worth $426K as of Q3 2019.
Boston Advisors sold 14,500 Intersect ENT, Inc shares in Q3 2019, an estimated $264K.
Intersect ENT, Inc made up 0.02% of Boston Advisors's portfolio in Q3 2019, its #474 holding.
Boston Advisors first reported a position in Intersect ENT, Inc in Q1 2017 and has held it in 11 quarters since.
Boston Advisors's Intersect ENT, Inc position peaked at $1.18M in Q2 2018.
112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2019.

Based on Boston Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.